BioShin Pharmaceuticals

CNS diseases


HBM contact: Dr Emil Bujak

BioShin is a development and commercialization company focused on advancing therapies for which there are currently no adequate treatment options. Our current clinical programs span a range of innovative, late-stage product candidates targeting neurological diseases. Bioshin is the Asia-Pacific subsidiary of Biohaven Pharmaceuticals.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171